|IP||0.5-2 μL/mg of lysate|
|ELISA(Det)||1:1000-1:10000||This antibody will detect Human C1 inhibitor / SerpinG1 in ELISA pair set (Catalog: # SEK10995). In a sandwich ELISA, it can be used as detection antibody when paired with (Catalog: # 10995-MM06).|
**********Please Note: Optimal concentrations/dilutions should be determined by the end user.**********
SERPING1 was immunoprecipitated using:
Lane A:0.5 mg HepG2 Whole Cell Lysate2 µL anti-SERPING1 rabbit monoclonal antibody and 15 μl of 50 % Protein G agarose.Primary antibody:
Anti-SERPING1 rabbit monoclonal antibody,at 1:100 dilutionSecondary antibody:
Dylight 800-labeled antibody to rabbit IgG (H+L), at 1:5000 dilutionDeveloped using the odssey technique.
Performed under reducing conditions.Predicted band size: 55 kDa
Observed band size: 100 kDa
Anti-SerpinG1 rabbit monoclonal antibody at 1:500 dilution
Lane A: HepG2 Whole Cell LysateLysates/proteins at 30 μg per lane.
Goat Anti-Rabbit IgG H&L (Dylight800) at 1/10000 dilution.Developed using the Odyssey technique.
Performed under reducing conditions.Predicted band size:55 kDa
Observed band size:71 kDa
Plasma protease C1 inhibitor, also known as C1-inhibiting factor, C1-INH, C1 esterase inhibitor, SERPING1 and C1IN, is a serine proteinase inhibitor (serpin) that regulates activation of both the complement and contact systems. By its C-terminal part (serpin domain), characterized by three beta-sheets and an exposed mobile reactive loop, C1-INH binds, and blocks the activity of its target proteases. The N-terminal end (nonserpin domain) confers to C1-INH the capacity to bind lipopolysaccharides and E-selectin. Owing to this moiety, C1-INH intervenes in regulation of the inflammatory reaction. The heterozygous deficiency of C1-INH results in hereditary angioedema (HAE). Owing to its ability to modulate the contact and complement systems and the convincing safety profile, plasma-derived C1 inhibitor is an attractive therapeutic protein to treat inflammatory diseases other than HAE. Deficiency of C1 inhibitor results in hereditary angioedema, which is characterized by recurrent episodes of localized angioedema of the skin, gastrointestinal mucosa or upper respiratory mucosa. C1 inhibitor may prove useful in a variety of other diseases including septic shock, reperfusion injury, hyperacute transplant rejection, traumatic and hemorrhagic shock, and the increased vascular permeability associated with thermal injury, interleukin-2 therapy and cardiopulmonary bypass.
|Product Description||Host||Clonality||Application||Catalog# (PDF)|
|Anti-C1 inhibitor Antibody||Mouse||Monoclonal||ELISA||10995-MM03|
|Anti-C1 inhibitor Antibody||Rabbit||Polyclonal||ELISA||10995-RP01|
|Anti-C1 inhibitor Antibody||Rabbit||Polyclonal||WB,ELISA,IHC-P||10995-RP02|
|Anti-C1 inhibitor Antibody||Mouse||Monoclonal||ELISA(Cap)||10995-MM06|